Childrens Memorial Hospital is the only Chicago site for a study to determine whether early treatment of eczema using one of a new class of anti-inflammatory drugs will prevent subsequent development of asthma and other allergic diseases. Prevalence of eczema, or atopic dermatitis, has tripled in the last few decades, in parallel with asthma. Investigators at Childrens Memorial are part of a national clinical trial involving 1,100 children, from 3 to 18 months old, to test pimecrolimus (Elidel), one of a new class of drugs called calcineurin inhibitors. Used in a cream form, pimecrolimus prevents the production of chemicals in the immune system that cause eczema symptoms, including redness, itching, cracking and bleeding.
The six-year prospective study, funded by Novartis, will be conducted in two stages. During the first three years a double blind study will compare the safety and effectiveness of pimecrolimus in conjunction with corticosteroid therapy for flare-ups, vs. corticosteroid therapy alone. Investigators hope that early treatment with pimecrolimus will reduce or prevent the need for corticosteroids. In the second three years, patients will be followed to see if they develop other allergic diseases, such as asthma, allergic rhinitis (hay fever), or allergic conjunctivitis (eye redness).
"The hope is that early and effective topical treatment of eczema in its early stages may help to prevent the later development of asthma, allergic rhinitis or allergic conjunctivitis," says Amy Paller, MD, lead site investigator and researcher at Childrens Memorial Institute for Education and Research. Paller, head of dermatology at Childrens Memorial, is professor of pediatrics and dermatology at Northwestern Universitys Feinberg School of Medicine.
Ellen M. Hunt | EurekAlert!
A promising target for kidney fibrosis
21.04.2017 | Brigham and Women's Hospital
Stem cell transplants: activating signal paths may protect from graft-versus-host disease
20.04.2017 | Technische Universität München
20.04.2017 | Event News
18.04.2017 | Event News
03.04.2017 | Event News
24.04.2017 | Physics and Astronomy
24.04.2017 | Materials Sciences
24.04.2017 | Life Sciences